Inactive Instrument

Alexion Pharmaceuticals, Inc. Stock price

Equities

ALXN

US0153511094

Pharmaceuticals

Dynamic Chart
Alexion Announces Long-Term Alpha Phase III Trial Data Shows Danicopan as Add-On to Standard of Care C5 Inhibitor Therapy ULTOMIRIS CI
Alexion Pharmaceuticals, Inc. completed the acquisition of Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc.. CI
Verge Genomics Announces Artificial Intelligence-Enabled Drug Discovery Collaboration with Alexion for Rare Neurodegenerative and Neuromuscular Diseases CI
Alexion Pharmaceuticals, Inc. entered a definitive purchase agreement to acquire Assets of early-stage rare disease gene therapy portfolio of Pfizer Inc. for $1 billion. CI
JCR Pharmaceuticals Co., Ltd. Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoR for Neurodegenerative Disease CI
Alexion Pharmaceuticals, Inc. completed the acquisition of LogicBio Therapeutics, Inc. from a group of shareholders. CI
Alexion Pharmaceuticals, Inc. Aims to Advance Nmosd Treatment Landscape with Exceptional Ultomiris® (Ravulizumab-Cwvz) Efficacy Data At Ectrims 2022 CI
Alexion Pharmaceuticals, Inc. entered into a definitive agreement to acquire LogicBio Therapeutics, Inc. from a group of shareholders for $68.2 million. CI
Alexion Pharmaceuticals, Inc Announces Danicopan Add-On to Ultomiris (Ravulizumab-Cwvz) or Soliris Met Primary Endpoint in Alpha Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experience Clinically Significant Extravascular Hemolysis CI
Alexion, Astrazeneca's Rare Disease Group and Neurimmune Closes Deal for Commercializing Ni006 CI
Alexion Enters into an Exclusive Global Collaboration and Licence Agreement with Neurimmune AG CI
Alexion Pharmaceuticals, Inc. completed the acquisition of remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others. CI
AstraZeneca's Alexion to Advance and Accelerate Ongoing Phase III Clinical Development of Cael-CAEL, a Potential Medicine for AL Amyloidosis CI
Alexion Pharmaceuticals, Inc. agreed to acquire remaining majority stake in Caelum Biosciences, Inc. from Fortress Biotech, Inc. and others for $500 million. CI
AstraZeneca : to Mandate COVID-19 Shots for US Staff MT
More news
Managers TitleAgeSince
Chief Executive Officer 71 -
Director of Finance/CFO - 21-07-31
Chief Tech/Sci/R&D Officer - 20-11-30
More insiders
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on discovering, development and commercialization of medicines. The Company's marketed products include ULTOMIRIS, SOLIRIS (eculizumab), STRENSIQ (asfotase alfa), KANUMA (sebelipase alfa) and ANDEXXA (coagulation Factor Xa - [recombinant] inactivated-zhzo). Its ULTOMIRIS product is a long-acting C5 inhibitor, that works by inhibiting the C5 protein in the terminal complement cascade. Its SOLIRIS product is a humanized monoclonal antibody that blocks terminal activity at the doses prescribed. Its Strensiq product is a targeted enzyme replacement therapy for patients with Hypophosphatasia (HPP). Its Kanuma product is a recombinant form of the human lysosomal acid lipase (LAL) enzyme. Its ANDEXXA product is a reversal agent for patients treated with rivaroxaban or apixaban.
More about the company
  1. Stock
  2. Equities
  3. Stock Alexion Pharmaceuticals, Inc. - Nasdaq